CURB-65 pneumonia severity score is an internationally validated clinical prediction rule designed to estimate mortality risk and guide site-of-care decisions for adult patients presenting with community-acquired pneumonia (CAP)^1,2. Developed by the British Thoracic Society as an evolution of the simpler BTS rule, CURB-65 assigns one point for each of five adverse prognostic indicators: acute Confusion, elevated blood Urea, high Respiratory rate, low Blood pressure, and advanced age (≥65 years)¹. By stratifying patients into distinct risk categories ranging from mild outpatient management to urgent intensive care unit (ICU) admission, the scoring system optimizes resource allocation, mitigates the risk of undertreating high-risk cohorts, and reduces unnecessary hospital admissions for low-risk individuals^1,2.

1. Etiology & Risk Factors

Primary Bacterial Pathogens: Streptococcus pneumoniae remains the most frequently isolated pathogen in community-acquired pneumonia across all severity scores. Other common bacterial agents include Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus (particularly post-influenza).
Atypical & Intracellular Pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila frequently present with systemic manifestations but can also drive severe pneumonia requiring inpatient hospitalization.
Viral Pathogens: Influenza A and B, respiratory syncytial virus (RSV), human metapneumovirus, and SARS-CoV-2 are major contributors, often leading to secondary bacterial superinfections that elevate the CURB-65 score.
Host Risk Factors: Advanced age (≥65 years, an independent CURB-65 parameter), chronic obstructive pulmonary disease (COPD), bronchiectasis, chronic kidney disease, congestive heart failure, diabetes mellitus, asplenia, chronic liver disease, and immunosuppressive therapies.
Environmental & Behavioral Triggers: Active smoking, alcohol abuse disorder, malnutrition, recent viral respiratory infections, and residence in long-term care facilities or nursing homes.

2. Pathophysiology

Inhalation or micro-aspiration of pathogens past the upper airway defense mechanisms establishes infection in the terminal bronchioles and alveoli, triggering a localized inflammatory response marked by alveolar macrophage activation, cytokine release, and neutrophil recruitment^1,2. This exudative phase leads to pulmonary edema, capillary congestion, and consolidation, creating a profound ventilation-perfusion ($V/Q$) mismatch that manifests as hypoxemic respiratory failure. As local inflammation spills into the systemic circulation, systemic inflammatory response syndrome (SIRS) ensues, characterized by peripheral vasodilation, capillary leak, and relative intravascular volume depletion. This hemodynamic instability results in renal hypoperfusion and acute uremia (urea >7 mmol/L), cerebral hypoperfusion and metabolic encephalopathy (acute confusion), and tachypnea driven by hypoxemia and metabolic acidosis. The cumulative physiological breakdown is captured by the five distinct parameters of the CURB-65 score, reflecting multi-organ stress and impending systemic collapse^1,2.

3. Clinical Presentation & Classic Clinical Signs

History & Cardinal Symptoms: Acute onset of productive cough (often with rust-colored or purulent sputum), pleuritic chest pain, dyspnea, rigors, high-grade fevers, fatigue, myalgias, and gastrointestinal symptoms such as nausea or diarrhea (classic in Legionella infections).
Physical Examination & Named Clinical Signs:
- Vital Sign Abnormalities: Tachypnea (respiratory rate ≥30 breaths/min), tachycardia, hypoxemia ($SpO_2 < 92\%$ on room air), and hypotension (systolic BP <90 mmHg or diastolic BP ≤60 mmHg).
- Neurological Assessment: Altered mental status, disorientation to time/place/person, or depressed abbreviated mental test score (AMTS ≤8).
- Auscultatory Findings: Focal bronchial breath sounds, crackles (rales), decreased breath sounds over the affected lung zone, and egophony ("E to A" changes indicating consolidation).
- Inspection Findings: Use of accessory muscles of respiration, intercostal recession, and cyanosis in severe cases.

4. Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test	Expected Clinical & Radiological / Laboratory Finding
Gold-Standard Investigation	Chest Radiograph demonstrating new or progressive focal lobar, interstitial, or multi-lobar consolidation combined with clinical and biochemical CURB-65 risk stratification^1,2.
Laboratory Panel	Complete blood count showing leukocytosis (>12,000/µL with a left shift) or leukopenia (<4,000/µL in severe sepsis); serum urea >7 mmol/L (BUN >19 mg/dL); serum electrolytes; elevated inflammatory markers (CRP, procalcitonin).
Imaging / Radiology (X-ray, US, CT, MRI)	Posteroanterior and lateral chest X-ray showing dense lobar consolidation; bedside lung ultrasound revealing B-lines, subpleural consolidations, and dynamic air bronchograms; chest CT reserved for complicated cases, abscesses, or empyema.
ECG / Histopathology / Procedural	12-lead ECG to rule out acute coronary syndrome or myocardial strain; arterial blood gas (ABG) analysis demonstrating acute hypoxemic respiratory failure with or without respiratory alkalosis/acidosis; sputum Gram stain and culture; blood cultures in severe cases.

5. Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component	Clinical Threshold, Points & Management Implication
C — Confusion	Abbreviated Mental Test Score (AMTS) ≤8 or new disorientation in person, time, or place (1 point).
U — Urea	Serum urea >7 mmol/L (BUN >19 mg/dL); reflects acute renal impairment and volume depletion (1 point).
R — Respiratory Rate	Respiratory rate ≥30 breaths per minute; indicates significant work of breathing and physiological distress (1 point).
B — Blood Pressure	Systolic blood pressure <90 mmHg or diastolic blood pressure ≤60 mmHg; indicates hemodynamic instability or sepsis (1 point).
65 — Age	Age ≥65 years; accounts for age-related decline in physiological reserve and immunological defense (1 point).
Score 0–1 (Low Risk)	30-day mortality <3%; suitable for outpatient oral antibiotic therapy and primary care monitoring.
Score 2 (Moderate Risk)	30-day mortality ~9%; warrants hospital admission for inpatient ward-based medical care and intravenous/oral therapy.
Score 3–5 (High Risk)	30-day mortality 15–40%+; mandates urgent hospital admission, intensive monitoring, and immediate consideration for ICU/HDU transfer.

6. Differential Diagnosis

Differential Condition	Distinguishing Clinical, Biochemical & Imaging Features
Acute Heart Failure / Pulmonary Edema	History of orthopnea, paroxysmal nocturnal dyspnea, elevated BNP/NT-proBNP, bilateral interstitial infiltrates, Kerley B lines on chest X-ray, and rapid response to diuretics.
Pulmonary Embolism	Acute pleuritic chest pain and dyspnea with disproportionate tachycardia; risk factors for DVT; Wells score; CT pulmonary angiography showing filling defects; normal chest X-ray in many cases.
Acute Exacerbation of COPD / Asthma	Prominent wheezing, baseline chronic respiratory symptoms, absence of focal lobar consolidation on chest radiograph, and response to bronchodilators and systemic corticosteroids.
Atelectasis	Volume loss with tracheal deviation toward the affected side, elevated hemidiaphragm, subsegmental opacities without air bronchograms, and absence of systemic infection signs.

7. Management & Treatment Protocol

Initial Stabilization & Resuscitation: Assess airway, breathing, and circulation (ABCDE approach). Administer supplemental oxygen to maintain target oxygen saturation ($SpO_2$ 94–98%, or 88–92% in chronic hypercapnic respiratory failure). Initiate aggressive intravenous fluid resuscitation if hypotension is present, while monitoring for fluid overload. Obtain blood cultures, sputum cultures, and initiate prompt antimicrobial therapy within 1 hour of presentation for severe cases.
First-Line Medical / Pharmacological Therapy (with exact adult dosing):
- Outpatient (CURB-65 Score 0–1): Oral Amoxicillin 500 mg to 1 g TDS for 5 days. For penicillin-allergic patients, use Doxycycline 100 mg BD (with a 200 mg loading dose) or Clarithromycin 500 mg BD.
- Inpatient, Moderate Severity (CURB-65 Score 2): Oral or IV Amoxicillin 500 mg to 1 g TDS plus Clarithromycin 500 mg BD for 7–10 days. Alternatively, use oral or IV Levofloxacin 500 mg OD as monotherapy.
- Inpatient, Severe / High Risk (CURB-65 Score ≥3): IV Co-amoxiclav 1.2 g TDS plus IV Clarithromycin 500 mg BD. If atypical pathogens or severe pseudomonal risk factors are present, consult local microbiology guidelines for expanded coverage (e.g., adding Vancomycin or Piperacillin-tazobactam).
Surgical / Interventional Indications: Diagnostic or therapeutic thoracentesis for parapneumonic effusions; chest tube insertion (tube thoracostomy) for frank empyema; video-assisted thoracoscopic surgery (VATS) for multiloculated or persistent pleural space infections.

8. Complications & Prognosis

Acute Complications: Septic shock, multiorgan dysfunction syndrome (MODS), acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), parapneumonic effusion, empyema, lung abscess, and venous thromboembolism.
Chronic & Long-Term Sequelae: Persistent functional impairment, prolonged post-pneumonia fatigue, chronic bronchiectasis, and increased long-term cardiovascular mortality following severe acute respiratory infections.
Prognosis & Mortality Data: Mortality scales directly with the CURB-65 score: a score of 0 carries a 30-day mortality of ~0.7%, a score of 1 carries ~3.2%, a score of 2 carries ~13%, a score of 3 carries ~17%, a score of 4 carries ~41.5%, and a score of 5 carries upwards of 57%. Prompt antibiotic administration and rigorous adherence to risk stratification guidelines significantly improve clinical outcomes.

Medipaedia.org

CURB-65 pneumonia severity score

⚡ At-a-Glance Clinical Summary Card